Two constructed antibody-derived delivery vehicles for targeting oligodeoxynucleotides to prostate tumors expressing prostate specific antigen.
We evaluated the ability of antibody-derived delivery vehicles (DVs) to direct synthetic biotinylated oligodeoxynucleotides (ODNs) to prostate tumors in vitro. A monoclonal mouse antibody raised against prostate-specific antigen (PSA) was modified by two approaches to produce either: (1) a bispecific delivery vehicle recognizing both PSA and biotin (DV(Hc)), or (2) an avidin-conjugated anti-PSA delivery vehicle (DV(PSA)). Immunoreactivity of the DVs and their ability to form complexes were tested in vitro. Although both DVs retained immunoreactivity and were able to form complexes with biotinylated ODNs, the avidin modification method was more efficient. This method may be useful for selective delivery of antisense ODNs to prostate tumors.
Mirochnik
Yelena
Y
Division of Cellular Biology, The Hektoen Institute for Medical Research, and Department of Biochemistry, Rush Presbyterian St. Lukes Medical Center, Chicago, Illinois 60612, USA.
Rubenstein
Marvin
M
Guinan
Patrick
P
D000818:Animals; D000906:Antibodies / Q000737:chemistry*; D001360:Avidin; D001710:Biotin; D016503:Drug Delivery Systems; D024202:Electrophoretic Mobility Shift Assay; D005455:Fluorescent Antibody Technique; D006801:Humans; D007074:Immunoglobulin G / Q000096:biosynthesis / Q000276:immunology; D007150:Immunohistochemistry; D008297:Male; D051379:Mice; D016376:Oligonucleotides, Antisense / Q000008:administration & dosage*; D014677:Pharmaceutical Vehicles; D017430:Prostate-Specific Antigen / Q000187:drug effects / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000378:metabolism*
D000906:Antibodies; D007074:Immunoglobulin G; D016376:Oligonucleotides, Antisense; D014677:Pharmaceutical Vehicles; D001360:Avidin; D001710:Biotin; D017430:Prostate-Specific Antigen